IOncology

With the continuous development and market release of new ADC drugs, the treatment landscape for breast cancer patients has changed. For patients with advanced breast cancer, the feasibility of using another ADC drug after the initial ADC treatment has become a common clinical concern. In the "In-depth Inquiry" segment of the 2024 North-South Meeting, Professor Ting Luo from West China Hospital of Sichuan University delivered a report titled "Rescue Treatment for Advanced Breast Cancer: ADC After ADC?". This article reviews the content of her lecture.

Urothelial carcinoma is one of the most common malignancies of the urinary system, with high incidence and mortality rates. Despite the efficacy of platinum-based chemotherapy as the standard first-line treatment for advanced urothelial carcinoma, researchers have been relentless in their pursuit of more effective and personalized treatment options. Recent breakthroughs in targeted therapies and immunotherapies have spurred the development of various combination therapies, bringing new hope to patients with advanced urothelial carcinoma. At the recently concluded 39th Annual Congress of the European Association of Urology (EAU24), Oncology Frontier had the privilege of interviewing Professor Thomas Powles from the University of London and Barts Cancer Institute. In this interview, Professor Powles detailed the current status and challenges in the field of advanced urothelial carcinoma, as well as future directions worth exploring.

The prevalence of robotic surgery in the treatment of early-stage breast cancer is not high, and there is significant debate over its necessity for these patients. At the 2024 South-North Forum, Prof. Li Ma from The Fourth Hospital of Hebei Medical University delivered a presentation on the topic "Is Robotic Surgery Necessary for Early-Stage Breast Cancer?" This article reviews the key points from his lecture.

The treatment of renal cancer includes surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. With advancements in treatment technologies, combining the latest modalities for comprehensive treatment of renal cancer is crucial for improving prognosis. The 39th Annual European Association of Urology (EAU24) Congress was held from April 5-8, 2024, in Paris, France, focusing on global urological oncology hotspots and forefront advancements from Chinese urological scholars. "Oncology Frontier" had the opportunity to interview Professor Qiang Wei from West China Hospital, Sichuan University, who shared insights into adjuvant immunotherapy for renal cancer, cytoreductive nephrectomy research, and robot-assisted radical nephrectomy.

The axillary lymph node burden after neoadjuvant therapy is closely related to prognosis. Unlike the assessment in initial surgery patients, residual tumor cells after neoadjuvant therapy are considered resistant cells. Thus, can limited sentinel lymph node biopsy (SLNB) metastasis after neoadjuvant therapy exempt patients from axillary lymph node dissection (ALND)? At the 2024 South-North Forum, Prof. Pengfei Qiu from Shandong Cancer Hospital presented a report titled "Do Breast Cancer Patients with cN1 Who Downstage to ycN0 after Neoadjuvant Therapy and Have Limited SLNB Metastasis Need ALND?" This article reviews the key points of his lecture.

Targeted therapy has always been a critical component of systemic treatment for HER2-positive breast cancer patients. Currently, small-molecule tyrosine kinase inhibitors (TKIs) are commonly used HER2-targeted therapies. What role do TKIs play in the neoadjuvant treatment of HER2-positive breast cancer, and what drug combinations yield the best treatment outcomes? At the 2024 South-North Forum, Prof. Junjie Li from Fudan University Cancer Hospital presented a report titled "What's Next for Neoadjuvant Therapy in HER2-Positive Breast Cancer?" This article compiles the key points from his lecture.

Kidney cancer surgical scoring systems provide critical information for treatment planning, surgical method selection, tumor recurrence risk, and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from April 5 to 8, 2024, in Paris, France, where numerous studies and advancements related to kidney cancer surgery were presented. Oncology Frontier invited Professor Jianming Guo from Zhongshan Hospital, Fudan University, to share insights on preoperative and postoperative scoring systems, AI predictions of kidney tumor pathology, and prognosis.

In early March, as the spring begins in Jiangcheng, the cherry blossoms bloom following the plum blossoms. The 4th Jiangcheng Breast Cancer Academic Forum was successfully held in Wuhan. Experts in breast cancer surgery, medical oncology, radiotherapy, and basic and translational research gathered to present numerous research advancements and clinical development trends. After the conference, Oncology Frontier invited the conference chair, Professor Jing Yao from Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, to share highlights of the conference and developments in breast cancer diagnosis and treatment.

The situation of urological tumors in China is not optimistic, with the incidence of kidney cancer increasing annually by 4% to 7%. There is an urgent need to explore new diagnostic and therapeutic strategies to improve incidence rates and patient prognosis. The 39th Annual Congress of the European Association of Urology (EAU24) was held from April 5 to 8, 2024, in Paris, France. Oncology Frontier invited Professor Tongyi Men from the Affiliated Hospital of Inner Mongolia Medical University to share his insights from the conference and advancements in kidney cancer research.

Breast diseases have the highest incidence among women, with breast cancer being the leading malignant tumor threatening women's health. From "one-size-fits-all" treatments to "individualized therapy" based on patients, the exploration of breast cancer treatment has been ongoing for centuries. At the 2024 South-North Forum, Prof. Zhiming Shao from Fudan University Cancer Hospital presented a report titled "Precision Typing Drives Diagnosis and Treatment Innovation: A New Model for Breast Cancer Precision Diagnosis and Treatment." This article introduces the key points of the report.